CDC Logo Tuberculosis Information CD-ROM   Image of people
     
jump over main navigation bar to content area
Home
TB Guidelines
Surveillance Reports
Slide Sets
TB-Related MMWRs and Reports
Education/Training Materials
Newsletters
Ordering Information
Help

 

U.S. Department of Health and Human Services

  

TB Guidelines

On this Page:

Treatment

Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis

PDF

Guidelines for the Investigation of Contacts of Persons with Infectious Tuberculosis: Recommendations from the National Tuberculosis Controllers Association and CDCMMWR 2005; 54 (No. RR-15, 1-37)
www.cdc.gov/mmwr/preview/mmwrhtml/rr5415a1.htm

PDF
MMWR: Errata: Treatment of Tuberculosis (Vol. 52, No. RR-11)
www.cdc.gov/mmwr/preview/mmwrhtml/mm5351a5.htm
PDF
Treating Opportunistic Infections Among HIV-Exposed and Infected Children - MMWR 2004; 53 (RR14)
www.cdc.gov/mmwr/preview/mmwrhtml/rr5314a1.htm
PDF

Tuberculosis Associated with Blocking Agents Against Tumor Necrosis Factor - Alpha - California, 2002–2003 - MMWR 2004; 53 (No. 30)
www.cdc.gov/mmwr/preview/mmwrhtml/mm5330a4.htm

PDF

Notice to Readers: Updated Guidelines for the Use of Rifamycins for the Treatment of Tuberculosis Among HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors - MMWR 2004; 53 (No. 2)
www.cdc.gov/mmwr/preview/mmwrhtml/mm5302a6.htm

PDF

Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection MMWR 2003; 52 (No. 31).
www.cdc.gov/mmwr/preview/mmwrhtml/mm5231a4.htm

PDF

Treatment of Tuberculosis MMWR 2003; 52 (No. RR-11)
www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm

PDF
  PDF
   

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection -  MMWR 2000; 49 (No. RR-6)
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4906a1.htm

PDF
 

Updated Guidelines for the Use of Rifabutin or Rifampin for the Treatment and Prevention of Tuberculosis Among HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors - MMWR 2000;  49 (No. 9)
www.cdc.gov/mmwr/preview/mmwrhtml/mm4909a4.htm

PDF

 

Archived Treatment

The documents listed below are historical, archived information. The information contained in these documents, while accurate at the time of release, may not be the most current available.

Public Health Dispatch: Update: Fatal and Severe Liver Injuries Associated with Rifampin and Pyrazinamide Treatment for Latent Tuberculosis Infection -  MMWR 2002; 51 (No. 44)
www.cdc.gov/mmwr/preview/mmwrhtml/mm5144a4.htm

PDF

Treatment of Tuberculosis and Tuberculosis Infection
Am J Respir Crit Care Med 1994; 149

PDF

Management of Persons Exposed to Multidrug-Resistant Tuberculosis.  MMWR 1992; 41 (RR-11)
www.cdc.gov/mmwr/preview/mmwrhtml/00031296.htm

N/A

 


Released October 2008
Centers for Disease Control and Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination - http://www.cdc.gov/tb

Please send comments/suggestions/requests to: hsttbwebteam@cdc.gov, or to
CDC/Division of Tuberculosis Elimination
Communications, Education, and Behavioral Studies Branch
1600 Clifton Rd., NE - Mailstop E-10, Atlanta, GA 30333